Interstitial photodynamic therapy in the canine prostate
- PMID: 9439405
- DOI: 10.1046/j.1464-410x.1997.00460.x
Interstitial photodynamic therapy in the canine prostate
Abstract
Objective: To determine the depth of tissue destruction and the minimum light dose required for necrosis in interstitial photodynamic therapy (PDT), as a prerequisite for the investigational therapy of patients.
Materials and methods: Seven adult beagle dogs were given 2 mg/kg of the photosensitizer Photofrin intravenously and two controls received none. After 24 h, 450 J/cm of 630 nm wavelength laser light was delivered interstitially to the prostate via a 2 cm long diffuser fibre. Seven single-fibre treatments were performed in five sensitized dogs and two single-fibre treatments in the controls. The two remaining sensitized dogs had two fibres placed 10 mm apart within the prostate to determine the coalescence of PDT lesions. The penetration depth of light was measured in all prostates, and after PDT the extent of necrosis was assessed histologically.
Results: The mean (standard deviation, SD) radius of PDT destruction around each diffuser was 5.3 (1.4) mm and PDT lesions overlapped in prostates treated with two fibres placed 10 mm apart. There was no observable tissue damage in the controls. The mean (SD) minimum light dose required for PDT necrosis was 84 (64) J/cm2. Differences among animals in the light penetration depth were small, with a mean of 2.14 (0.2) mm, and did not correlate with the depth of necrosis (P = 0.07). Bleeding around the optical diffuser fibre impeded light penetration.
Conclusion: Interstitial PDT in the canine prostate using Photofrin produced modest volumes of tissue necrosis. The minimum light dose required to induce necrosis was variable because bleeding was unpredictable in relation to the optical fibre.
Similar articles
-
Laser dosimetry studies in the prostate.J Clin Laser Med Surg. 1998 Feb;16(1):9-12. doi: 10.1089/clm.1998.16.9. J Clin Laser Med Surg. 1998. PMID: 9728124 Review.
-
Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.Photochem Photobiol. 2002 Oct;76(4):438-45. doi: 10.1562/0031-8655(2002)076<0438:PSINCP>2.0.CO;2. Photochem Photobiol. 2002. PMID: 12405153
-
Photodynamic therapy in the canine prostate using motexafin lutetium.Clin Cancer Res. 2001 Mar;7(3):651-60. Clin Cancer Res. 2001. PMID: 11297261
-
Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer PEG-m-THPC.Br J Cancer. 1999 Oct;81(4):631-7. doi: 10.1038/sj.bjc.6690740. Br J Cancer. 1999. PMID: 10574248 Free PMC article.
-
Photodynamic therapy: a new approach to prostate cancer.Curr Urol Rep. 2003 Jun;4(3):221-8. doi: 10.1007/s11934-003-0073-4. Curr Urol Rep. 2003. PMID: 12756086 Review.
Cited by
-
Optimized interstitial PDT prostate treatment planning with the Cimmino feasibility algorithm.Med Phys. 2005 Dec;32(12):3524-36. doi: 10.1118/1.2107047. Med Phys. 2005. PMID: 16475751 Free PMC article. Clinical Trial.
-
Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy.Photochem Photobiol. 2005 Jan-Feb;81(1):96-105. doi: 10.1562/2004-06-25-RA-216. Photochem Photobiol. 2005. PMID: 15535736 Free PMC article. Clinical Trial.
-
Photodynamic therapy for focal ablation of the prostate.World J Urol. 2010 Oct;28(5):571-6. doi: 10.1007/s00345-010-0554-2. Epub 2010 May 9. World J Urol. 2010. PMID: 20454966 Review.
-
Prostate PDT dosimetry.Photodiagnosis Photodyn Ther. 2006 Dec;3(4):234-46. doi: 10.1016/j.pdpdt.2006.08.002. Epub 2006 Oct 19. Photodiagnosis Photodyn Ther. 2006. PMID: 25046988 Free PMC article.
-
In-vivo light dosimetry of interstitial PDT of human prostate.Proc SPIE Int Soc Opt Eng. 2006 Jan 21;6139:61390L. doi: 10.1117/12.646220. Proc SPIE Int Soc Opt Eng. 2006. PMID: 26113758 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical